Rilzabrutinib significantly reduces itch and hives in patients with chronic spontaneous urticaria unresponsive to ...

Sanofi SNY reported first-quarter 2025 adjusted earnings of 94 cents per American depositary share, which beat the Zacks ...

Sanofi and Regeneron's Dupixent (dupilumab) has been approved by the FDA for the treatment of chronic spontaneous urticaria ...

Sanofi has not had the success it was hoping for with its oral BTK inhibitors, acquired as part of its $3.7 billion buyout of Principia Biopharma, but can now point to a win for rilzabrutinib in ...

Retifanlimab with platinum-based chemotherapy for treating inoperable, locally recurrent or metastatic squamous cell anal canal cancer untreated with systemic chemotherapy [ID6482] Technology ...

locally recurrent or metastatic squamous cell anal canal cancer untreated with systemic chemotherapy [ID6482] Technology appraisal guidance Rilzabrutinib for treating persistent or chronic immune ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Prolonged neonatal thrombocytopenia in FNAIT can occur in the absence of anti-HPA antibodies, with anti-HLA-A11, -B3901, and -Cw7 antibodies potentially contributing. Antihuman leukocyte antigen (HLA) ...

As of 2:38:16 pm GMT+7. Market open.

The simplified requirements for Camzyos are expected to ease prior contraindications, thereby simplifying treatment and expanding eligibility in patients with symptomatic New York Heart Association ...